Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05878951 · ClinicalTrials.gov registry record · Phase 2
Examining the Effects of Intra-detrusor Botox at Time of HoLEP in Men With Overactive Bladder Symptoms
A Phase 2 study of Urinary Incontinence and Overactive Bladder, sponsored by Northwestern University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
- 1
- Study location
NCT05878951 is a Phase 2 study of Urinary Incontinence and Overactive Bladder that is actively recruiting participants, run by Northwestern University. The registered enrollment target is 80 participants, below the 260-participant average among 48 other Urinary Incontinence trials with a reported enrollment target (69% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05878951, a Phase 2 study of Urinary Incontinence and Overactive Bladder, is actively recruiting participants, sponsored by Northwestern University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of our multi-center randomized single-blind study is to examine the safety and effect of intra-detrusor OnabotulinumtoxinA injections at the time of holium laser enucleation of the prostate (HoLEP) in men with overactive bladder symptoms with and without urge incontinence.
Conditions Studied
Interventions
- DRUG OnabotulinumtoxinA
Study Locations (1)
Illinois
- Northwestern Medicine - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2023-07-13 |
| Est. Completion | 2026-08-24 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05878951
The ClinicalTrials.gov registry entry for NCT05878951 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 260-participant average among 48 other Urinary Incontinence trials with a reported enrollment target (69% lower). The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Urinary Incontinence appearing as the primary indexed condition, and to 1 intervention - of which OnabotulinumtoxinA is the first listed.
NCT05878951 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT05878951 about?
NCT05878951 is a clinical study titled "Examining the Effects of Intra-detrusor Botox at Time of HoLEP in Men With Overactive Bladder Symptoms". The objective of our multi-center randomized single-blind study is to examine the safety and effect of intra-detrusor OnabotulinumtoxinA injections at the time of holium laser enucleation of the prostate (HoLEP) in men with overactive bladder symptoms with and without urge incontinence.
What is the current status of trial NCT05878951?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2023-07-13. Estimated completion is 2026-08-24.
What conditions does trial NCT05878951 study?
This clinical trial studies the following conditions: Urinary Incontinence, Overactive Bladder, Overactive Bladder Syndrome, Urologic Diseases.
What interventions are being tested in trial NCT05878951?
The interventions under investigation include: OnabotulinumtoxinA (DRUG).
Who is sponsoring clinical trial NCT05878951?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05878951 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Urinary Incontinence
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sildenafil for Treatment of Urinary Incontinence in Patients With Spinal Cord Injuries
RECRUITING · Phase 2
-
CBD for Lower Urinary Tract Dysfunction in Spinal Cord Injury
RECRUITING · Phase 2
-
Comparison of Surgical Procedures to Reduce Urinary Stress Incontinence
COMPLETED · Phase 2
-
Study to Evaluate the Safety and Efficacy of DR-3001 Versus Placebo in Women With Overactive Bladder
COMPLETED · Phase 2
-
Urge Incontinence Bladder Overactivity Study
COMPLETED · Phase 2
-
Translating Unique Learning for Incontinence Prevention
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.